Home > Insider Trading > Filing (0000899243-17-017838)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1420565	Aileron Therapeutics Inc	ALRN	Pharmaceutical Preparations (2834)	V8

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1114448	Ag Novartis	Lichtstrasse 35 Basel V8 CH 4056		No	No	Yes	No
1297709	Ltd Bioventures Novartis	C/O Novartis International Ag Wsj-200.220 Basel V8 CH-4002		No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2017-07-05	2,277,515	$0.00	2,277,515	No	4	C	Direct
Common Stock	Acquisiton	2017-07-05	266,667	$15.00	2,544,182	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Direct
No	4	P	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series C Preferred Stock	Disposition	2017-07-05	2,967,025	$0.00	298,583	$0.00
Common Stock	Series C-2 Preferred Stock	Disposition	2017-07-05	4,238,607	$0.00	426,547	$0.00
Common Stock	Series D Preferred Stock	Disposition	2017-07-05	6,781,770	$0.00	682,476	$0.00
Common Stock	Series E-2 Preferred Stock	Disposition	2017-07-05	2,644,558	$0.00	266,132	$0.00
Common Stock	Series E-3 Preferred Stock	Disposition	2017-07-05	2,293,829	$0.00	230,837	$0.00
Common Stock	Series F Preferred Stock	Disposition	2017-07-05	3,705,882	$0.00	372,937	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Direct
No	4	C	Direct
No	4	C	Direct
No	4	C	Direct
No	4	C	Direct
No	4	C	Direct

Footnotes

The Series C, Series C-2, Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C, Series C-2, Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date.
The shares are directly owned by Novartis Bioventures Ltd. Novartis Bioventures Ltd. is a wholly-owned indirect subsidiary of Novartis AG, which is an indirect beneficial owner of the reported securities.
Novartis Bioventures Ltd., a wholly-owned indirect subsidiary of Novartis AG, acquired 266,667 shares of Common Stock in the Issuer's initial public offering.